De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Seagen Toekomstige groei

Future criteriumcontroles 6/6

Seagen zal naar verwachting groeien in winst en omzet met respectievelijk 71.8% en 22.6% per jaar. De winst per aandeel zal naar verwachting groeien met 71.5% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 21.6% zijn.

Belangrijke informatie

71.8%

Groei van de winst

71.5%

Groei van de winst per aandeel

Biotechs winstgroei	28.7%
Inkomstengroei	22.6%
Toekomstig rendement op eigen vermogen	21.6%
Dekking van analisten	Good
Laatst bijgewerkt	14 Dec 2023

Recente toekomstige groei-updates

Recent updates

Seagen Inc.'s (NASDAQ:SGEN) Popularity With Investors Is Under Threat From Overpricing

Dec 12

A Look At The Fair Value Of Seagen Inc. (NASDAQ:SGEN)

Apr 17

Here's Why We're Not At All Concerned With Seagen's (NASDAQ:SGEN) Cash Burn Situation

Mar 20

An Intrinsic Calculation For Seagen Inc. (NASDAQ:SGEN) Suggests It's 47% Undervalued

Dec 09

Here's Why We're Not At All Concerned With Seagen's (NASDAQ:SGEN) Cash Burn Situation

Oct 14

Winst- en omzetgroeiprognoses

NasdaqGS:SGEN - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2025	4,080	180	421	564	13
12/31/2024	3,181	-335	32	96	16
12/31/2023	2,428	-754	-361	-372	17
9/30/2023	2,300	-750	-701	-540	N/A
6/30/2023	2,162	-725	-723	-590	N/A
3/31/2023	2,056	-649	-585	-487	N/A
12/31/2022	1,962	-610	-531	-454	N/A
9/30/2022	1,864	-637	-719	-658	N/A
6/30/2022	1,778	-740	-652	-590	N/A
3/31/2022	1,669	-690	-653	-590	N/A
12/31/2021	1,574	-674	-551	-499	N/A
9/30/2021	1,746	-333	-82	-26	N/A
6/30/2021	2,383	597	756	814	N/A
3/31/2021	2,273	661	736	800	N/A
12/31/2020	2,176	614	774	857	N/A
9/30/2020	1,864	472	571	656	N/A
6/30/2020	1,016	-256	-312	-228	N/A
3/31/2020	956	-314	-259	-176	N/A
12/31/2019	917	-159	-234	-164	N/A
9/30/2019	801	-304	-234	-176	N/A
6/30/2019	758	-280	-172	-127	N/A
3/31/2019	709	-124	-143	-114	N/A
12/31/2018	655	-223	-225	-204	N/A
9/30/2018	610	-162	-183	-182	N/A
6/30/2018	576	-45	-179	-179	N/A
3/31/2018	514	-177	-221	-203	N/A
12/31/2017	482	-126	-148	-119	N/A
9/30/2017	458	-121	-183	-132	N/A
6/30/2017	429	-203	N/A	-155	N/A
3/31/2017	416	-180	N/A	-143	N/A
12/31/2016	418	-140	N/A	-97	N/A
9/30/2016	406	-110	N/A	-101	N/A
6/30/2016	384	-105	N/A	-110	N/A
3/31/2016	366	-119	N/A	-124	N/A
12/31/2015	337	-120	N/A	-133	N/A
9/30/2015	318	-122	N/A	-135	N/A
6/30/2015	309	-111	N/A	-106	N/A
3/31/2015	301	-82	N/A	-64	N/A
12/31/2014	287	-76	N/A	-60	N/A
9/30/2014	280	-65	N/A	-33	N/A
6/30/2014	275	-73	N/A	9	N/A
3/31/2014	280	-63	N/A	6	N/A
12/31/2013	269	-63	N/A	-1	N/A
9/30/2013	266	-57	N/A	43	N/A
6/30/2013	245	-47	N/A	-12	N/A
3/31/2013	220	-58	N/A	9	N/A
12/31/2012	211	-54	N/A	11	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er wordt voorspeld dat SGEN de komende 3 jaar winstgevend zal worden, wat wordt beschouwd als een snellere groei dan de spaarquote ( 2.2% ).

Winst versus markt: Er wordt verwacht dat SGEN de komende 3 jaar winstgevend zal worden. Dit wordt gezien als een groei die boven het gemiddelde van de markt ligt.

Hoge groeiwinsten: Er wordt verwacht dat SGEN binnen 3 jaar winstgevend zal worden.

Omzet versus markt: De omzet van SGEN ( 22.6% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.7% per jaar).

Hoge groei-inkomsten: De omzet van SGEN ( 22.6% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen SGEN zal naar verwachting over 3 jaar hoog zijn ( 21.6 %)

Seagen Toekomstige groei

Future criteriumcontroles 6/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus EPS estimates fall by 12%, revenue upgraded

Price target increased by 7.3% to US$216

Price target increased by 7.7% to US$181

Consensus EPS estimates fall by 22%

Price target decreased to US$166

Price target decreased to US$169

Recent updates

Seagen Inc. Files Form 15

Seagen Inc.(NasdaqGS:SGEN) dropped from FTSE All-World Index (USD)

Pfizer Inc. (NYSE:PFE) completed the acquisition of Seagen Inc. (NasdaqGS:SGEN) from Baker/Tisch Investments, L.P, a funds managed by Baker Brothers Investments and others.

Seagen Inc.'s (NASDAQ:SGEN) Popularity With Investors Is Under Threat From Overpricing

Seagen Inc. Announces Phase 2 Study Evaluating the Antibody-Drug Conjugate ADCETRIS (brentuximab Vedotin) in Combination with the PD-1 Inhibitor Nivolumab and Standard Chemotherapy Agents Doxorubicin and Dacarbazine

Seagen Inc. Announces Data from the Phase 3 HER2CLIMB-02 Clinical Trial of TUKYSA

Astellas Pharma Inc. and Seagen Inc. Announces FDA Grants Priority Review for Supplemental Biologics License Application of Padcev with Keytruda for First-Line Treatment of Advanced Bladder Cancer

Seagen Inc. Announces FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

Chief Technical Officer notifies of intention to sell stock

Seagen Highlights First Solid Tumor Data for an ADCETRIS® (brentuximab vedotin) Immunotherapy Combination and Preclinical Data for Novel CD30-Directed Antibody-Drug Conjugate at Society for Immunotherapy of Cancer (SITC) Annual Meeting

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Genmab A/S and Seagen Inc. Announce Additional Results from the Phase 3 innovaTV 301 Randomized Global Trial

Seagen Inc. Announces to Highlight Overall Survival Data for Padcev and Tivdak During Presidential Symposium At Esmo Congress 2023

Seagen Inc. to Report Q3, 2023 Results on Nov 01, 2023

Astellas Pharma Inc. and Seagen Inc. Announces Positive Topline Results from the Phase 3 Ev-302 Clinical Trial

Chief Technical Officer notifies of intention to sell stock

Seagen Inc. and Genmab A/S Announce That Tivdak(R) (Tisotumab Vedotin-Tftv) Met Its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy

Insider notifies of intention to sell stock

Seagen Inc. Announces Phase 3 HER2CLIMB-02 Clinical Trial of TUKYSA®? (tucatinib) in Combination with Antibody-Drug Conjugate Ado-Trastuzumab Emtansine

Consensus EPS estimates fall by 12%, revenue upgraded

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Seagen Inc. to Report Q2, 2023 Results on Aug 02, 2023

Seagen Inc. Announces Phase 3 Trial of Adcetris (Brentuximab Vedotin) with Modified Chemo Regimen Shows Non-Inferiority with Unprecedented 3-Year Progression Free Survival of 94.9% Vs Less Tolerable International Standard of Care in Advanced Classical Hodgkin Lymphoma

Seagen Announces ADCETRIS® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 98% Overall Response Rate and 93% Complete Response Rate in Patients with Early-Stage Classical Hodgkin Lymphoma (cHL)

Chief Technical Officer notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Independent Director notifies of intention to sell stock

First quarter 2023 earnings: EPS misses analyst expectations

Price target increased by 7.3% to US$216

Insider notifies of intention to sell stock

A Look At The Fair Value Of Seagen Inc. (NASDAQ:SGEN)

Chief Financial Officer exercised options and sold US$8.8m worth of stock

Independent Director notifies of intention to sell stock

Here's Why We're Not At All Concerned With Seagen's (NASDAQ:SGEN) Cash Burn Situation

Price target increased by 7.7% to US$181

Chief Financial Officer notifies of intention to sell stock

Chief Financial Officer notifies of intention to sell stock

Consensus EPS estimates fall by 22%

Independent Director exercised options to buy US$1.4m worth of stock.

Full year 2022 earnings: EPS and revenues exceed analyst expectations

President of Research & Development notifies of intention to sell stock

President of Research & Development notifies of intention to sell stock

Chief Legal Officer notifies of intention to sell stock

Seagen Inc. to Report Q4, 2022 Results on Feb 15, 2023

President of Research & Development notifies of intention to sell stock

Seagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer

Independent Director exercised options to buy US$1.1m worth of stock.

Seagen Inc. Announces Results from Phase 2 Clinical Trial of ADCETRIS® (brentuximab vedotin) with Novel Immunotherapy Combination in Patients with Advanced- and Early-Stage Classical Hodgkin Lymphoma

An Intrinsic Calculation For Seagen Inc. (NASDAQ:SGEN) Suggests It's 47% Undervalued

Price target decreased to US$166

Chief Legal Officer exercised options to buy US$171k worth of stock.

Independent Director recently sold US$968k worth of stock

Seagen Inc. Announces U.S. FDA Approval of New Indication for Adcetris® (Brentuximab Vedotin) for Children with Previously Untreated High Risk Hodgkin Lymphoma

Price target decreased to US$169

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Seagen Inc. Revises Revenue Guidance for the Full Year of 2022

Chief Medical Officer & Interim CEO notifies of intention to sell stock

Here's Why We're Not At All Concerned With Seagen's (NASDAQ:SGEN) Cash Burn Situation

Seagen Inc. to Report Q3, 2022 Results on Oct 27, 2022

Seagen: A Stellar Portfolio Anchor

Seagen in licensing deal with Lava Therapeutics for cancer candidate

Seagen Inc. Announces TUKYSA® (tucatinib) in Combination with Trastuzumab Granted Priority Review by FDA for Previously Treated HER2-Positive Metastatic Colorectal Cancer

Seagen ticks lower as management suggests it could look at acquisitions

Astellas, Seagen and Merck Announce Results of Clinical Trial Investigating PADCEV(R) (Enfortumab Vedotin-Ejfv) with KEYTRUDA((R) (Pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urothelial Cancer

Seagen to Highlight Research in Urothelial and Colorectal Cancers At 2022 European Society for Medical Oncology (Esmo) Congress

Chief Medical Officer & Interim CEO notifies of intention to sell stock

Merck’s Reportedly Talks to Acquire Seagen Hit Snag, Threatening Mega Pharma Deal

Merck's talks with Seagen said to hit obstacle over price - report